Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

February is Age-Related Macular Degeneration Awareness (AMD) month. While AMD might be unfamiliar to some, nearly half a million people in Quebec are affected by this disease, which is the leading ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research ...

These are the best vitamins and supplements for eye health, which are great for supporting your vision and helping you take ...

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.

As people get older, two of the biggest health concerns are dementia and eye diseases like macular degeneration and cataracts ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.

Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...

Engineering students like An Le (left) and Bo Wen (center) work with Professor Truong Nguyen (right) to develop AI tools that ...